Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) General Counsel Sells $154,654.89 in Stock

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) General Counsel Bryan Wahl sold 3,341 shares of the business’s stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $46.29, for a total value of $154,654.89. Following the sale, the general counsel now owns 58,057 shares in the company, valued at $2,687,458.53. The trade was a 5.44 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Bryan Wahl also recently made the following trade(s):

• On Thursday, March 20th, Bryan Wahl sold 3,084 shares of Tarsus Pharmaceuticals stock. The stock was sold at an average price of $50.11, for a total value of $154,539.24.

Tarsus Pharmaceuticals Price Performance

Shares of NASDAQ TARS opened at $49.97 on Friday. The company has a debt-to-equity ratio of 0.30, a current ratio of 5.42 and a quick ratio of 5.38. The firm’s 50 day simple moving average is $48.48 and its 200-day simple moving average is $45.35. Tarsus Pharmaceuticals, Inc. has a 12 month low of $20.08 and a 12 month high of $57.28. The stock has a market capitalization of $1.92 billion, a price-to-earnings ratio of -13.12 and a beta of 1.05.

Tarsus Pharmaceuticals (NASDAQ:TARS) last released its quarterly earnings data on Tuesday, February 25th. The company reported ($0.60) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.68) by $0.08. Tarsus Pharmaceuticals had a negative net margin of 103.64% and a negative return on equity of 55.86%. The company had revenue of $66.41 million during the quarter, compared to analysts’ expectations of $58.80 million. Analysts expect that Tarsus Pharmaceuticals, Inc. will post -3.17 EPS for the current year.

Hedge Funds Weigh In On Tarsus Pharmaceuticals

Large investors have recently bought and sold shares of the business. Toronto Dominion Bank acquired a new stake in Tarsus Pharmaceuticals in the fourth quarter valued at approximately $105,714,000. GF Fund Management CO. LTD. acquired a new stake in Tarsus Pharmaceuticals in the 4th quarter valued at $44,000. Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. purchased a new stake in Tarsus Pharmaceuticals in the 4th quarter worth $3,278,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in Tarsus Pharmaceuticals by 18.7% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 69,826 shares of the company’s stock worth $3,866,000 after acquiring an additional 10,991 shares during the period. Finally, Woodline Partners LP lifted its holdings in Tarsus Pharmaceuticals by 52.3% during the fourth quarter. Woodline Partners LP now owns 108,986 shares of the company’s stock valued at $6,035,000 after purchasing an additional 37,417 shares in the last quarter. Institutional investors and hedge funds own 90.01% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently weighed in on TARS. Oppenheimer boosted their price target on Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 22nd. Jefferies Financial Group raised their price target on shares of Tarsus Pharmaceuticals from $54.00 to $58.00 and gave the stock a “buy” rating in a research report on Thursday, March 6th. Guggenheim reaffirmed a “buy” rating and issued a $78.00 price objective (up from $75.00) on shares of Tarsus Pharmaceuticals in a report on Monday, February 24th. Barclays cut their price objective on shares of Tarsus Pharmaceuticals from $62.00 to $60.00 and set an “overweight” rating on the stock in a research note on Wednesday, February 26th. Finally, HC Wainwright restated a “buy” rating and set a $73.00 target price on shares of Tarsus Pharmaceuticals in a research report on Wednesday, February 26th. One equities research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Tarsus Pharmaceuticals presently has a consensus rating of “Buy” and a consensus price target of $63.67.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.